Skip to main content

Black Diamond Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 16, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 16, 2026

BDTX$1.86+7.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Balance Sheets

(in thousands, except share and per share data)

December 31,
20252024
Assets
Current assets:
Cash and cash equivalents$20,990$36,437
Investments107,66262,138
Prepaid expenses and other current assets3,7882,601
Total current assets132,440101,176
Property and equipment, net3651,387
Restricted cash829819
Right-of-use assets9,30319,009
Other non-current assets73249
Total assets$143,010$122,640
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$579$4,007
Accrued expenses and other current liabilities15,15216,566
Total current liabilities15,73120,573
Non-current operating lease liability15,06818,782
Total liabilities30,79939,355
Commitments and contingencies (Note 12)——
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares and 10,000,000 shares authorized at December 31, 2025 and 2024, respectively; no shares issued or outstanding at December 31, 2025 and 2024——
Common stock; $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and 500,000,000 shares authorized at December 31, 2024; 57,138,057 shares issued and outstanding at December 31, 2025 and 56,644,655 shares issued and outstanding at December 31, 202487
Additional paid-in capital576,842570,361
Accumulated other comprehensive income (loss)10124
Accumulated deficit(464,740)(487,107)
Total stockholders' equity112,21183,285
Total liabilities and stockholders' equity$143,010$122,640
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.